RICCIO, ELEONORA
 Distribuzione geografica
Continente #
NA - Nord America 1.038
EU - Europa 620
AS - Asia 300
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
SA - Sud America 1
Totale 1.963
Nazione #
US - Stati Uniti d'America 1.027
IT - Italia 411
CN - Cina 152
VN - Vietnam 124
IE - Irlanda 52
NL - Olanda 52
FI - Finlandia 34
UA - Ucraina 13
DE - Germania 11
FR - Francia 11
CA - Canada 10
SE - Svezia 10
BG - Bulgaria 9
GB - Regno Unito 9
IN - India 9
TR - Turchia 5
JP - Giappone 4
RO - Romania 4
CH - Svizzera 3
EU - Europa 3
IR - Iran 2
SG - Singapore 2
AU - Australia 1
ES - Italia 1
IL - Israele 1
MX - Messico 1
PE - Perù 1
PK - Pakistan 1
Totale 1.963
Città #
Chandler 222
Napoli 129
Dong Ket 124
Millbury 82
Beijing 60
Des Moines 53
Amsterdam 50
Nanjing 42
Princeton 41
Lawrence 32
Naples 30
Boston 28
Wilmington 24
Caserta 22
Dublin 21
Jacksonville 13
Hebei 12
Nanchang 10
Ottawa 10
Sciacca 10
Duncan 9
Redwood City 9
Sofia 9
Jiaxing 8
Fairfield 6
Milan 6
Rome 6
Houston 5
New York 5
Riccione 5
Sesto San Giovanni 5
Tianjin 5
Woodbridge 5
Bucharest 4
Marano Di Napoli 4
Norwalk 4
Shenyang 4
Ashburn 3
Augusta 3
Baar 3
Brescia 3
Changsha 3
Istanbul 3
Maddaloni 3
Menlo Park 3
Nardò 3
Pomezia 3
San Giorgio Ionico 3
Seattle 3
Absecon 2
Ann Arbor 2
Baronissi 2
Boardman 2
Colorado Springs 2
Crespano Del Grappa 2
Erice 2
Frankfurt am Main 2
Frattamaggiore 2
Giugliano In Campania 2
Gragnano 2
Halle 2
Hangzhou 2
Jinan 2
Las Vegas 2
Milazzo 2
Ningbo 2
Perugia 2
Piano Di Sorrento 2
San Mateo 2
Sant'arpino 2
Stockholm 2
Tokyo 2
Abano Terme 1
Afragola 1
Altamura 1
Ardabil 1
Bologna 1
Brusciano 1
Callao 1
Casalnuovo Di Napoli 1
Casalnuovo di Napoli 1
Casoria 1
Castelfranco Veneto 1
Castelpoto 1
Cellole 1
Centrale 1
Columbus 1
Cormeilles-en-Parisis 1
Curinga 1
Eboli 1
Edison 1
Enna 1
Erftstadt 1
Ficarazzi 1
Forlì 1
Fuzhou 1
Gela 1
Genova 1
Grumo Nevano 1
Haifa 1
Totale 1.224
Nome #
Il nefrologo nel trattamento dell’iperammoniemia da disordini del ciclo dell’urea 65
Parapelvic cysts, a distinguishing feature of renal Fabry Disease. 65
Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer 61
Immunosuppression and multiple primary malignancies in kidney transplanted patients. A single-institute study 56
Plasma p-Cresol Lowering Effect of Sevelamer in Peritoneal Dialysis Patients: Evidence from a Cross-Sectional Observational Study. 51
6-tips diet: a simplified dietary approach in patients with chronic renal disease. A clinical randomized trial 51
Molecular Mechanisms of Renal Cellular Nephrotoxicity due to Radiocontrast Media 49
Hybrid positron emission tomography-magnetic resonance imaging for assessing different stages of cardiac impairment in patients with Anderson-Fabry disease: AFFINITY study group 46
Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study 46
Default mode network modifications in Fabry disease: A resting-state fMRI study with structural correlations 46
Current tissue molecular markers in colorectal cancer: A literature review 44
Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis 44
A strange epigastric pain. 43
Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial 43
Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis 42
Evidence That p-Cresol and IL-6 Are Adsorbed by the HFR Cartridge: Towards a New Strategy to Decrease Systemic Inflammation in Dialyzed Patients? 41
Early Cardiac Involvement Affects Left Ventricular Longitudinal Function in Females Carrying α-Galactosidase A Mutation: Role of Hybrid Positron Emission Tomography and Magnetic Resonance Imaging and Speckle-Tracking Echocardiography 40
Cerebrovascular and Brain Abnormalities In Autosomal-Dominant Polycystic Kidney Disease: Role Of 3d Time-of-Flight Magnetic Resonance Angiography 38
Pituitary function and morphology in Fabry disease. 36
Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial 36
Treatment with Agalsidase Alfa during Pregnancy in a Heterozygous Female with Fabry Disease 35
Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease 35
Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study 32
ADPKD and metformin: from bench to bedside 32
Terapia enzimatica sostitutiva nella malattia di Fabry: cosa abbiamo imparato dallo switch? 31
Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by (123)I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease 30
Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature 30
Nutritional management in renal transplant recipients: A transplant team opportunity to improve graft survival 30
ROLE OF HFR CARTRIDGE IN THE REMOVAL OF MEDIATORS OF INFLAMMATION IN HEMODIALYSIS PATIENTS 29
Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease. 29
Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease 29
Prominent longitudinal strain reduction of left ventricular basal segments in treatment-naïve Anderson-Fabry disease patients 29
Optical Coherence Tomography Angiography Findings in Fabry Disease 29
Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995–2019 29
Renal sympathetic-nerve ablation for uncontrolled hypertension in a patient with single-kidney autosomal dominant polycystic kidney disease. 28
Genetic variants associated with gastrointestinal symptoms in Fabry disease. 28
Endothelial-mediated coronary flow reserve in patients with Anderson-Fabry disease 27
Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: A randomized trial 27
Focal reduction in left ventricular 123I-metaiodobenzylguanidine uptake and impairment in systolic function in patients with Anderson-Fabry disease 27
Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study 26
Does left ventricular function predict cardiac outcome in Anderson-Fabry disease? 26
Atrial septum aneurysm: an unusual manifestation in ADPKD? 25
Fabry's disease: a comparison of the effectiveness of two different enzyme replacement therapies 24
Nutritional treatment in chronic kidney disease: the concept of nephroprotection. 24
Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients 24
Reduced intracranial volume in Fabry Disease: Evidence of abnormal neurodevelopment? 24
The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials 24
Early Biomarkers of Fabry Nephropathy: A Review of the Literature. 23
Immunomodulatory Effect of Continuous Venovenous Hemofiltration during Sepsis: Preliminary Data 22
Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis. 21
Glomerular Hyperfiltration: An Early Marker of Nephropathy in Fabry Disease 20
Experimental evidence and clinical implications of Warburg effect in the skeletal muscle of Fabry disease 20
The potential use of biomarkers in predicting contrast-induced acute kidney injury. 19
Renal denervation in ADPKD: an exceptional case 19
Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial 18
Genetic variants associated with Fabry disease progression despite enzyme replacement therapy 18
Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol 18
Fanconi syndrome with lysinuric protein intolerance 17
Molecular and clinical studies in five index cases with novel mutations in the GLA gene. 17
Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact? 17
Layer-specific longitudinal strain in Anderson–Fabry disease at diagnosis: A speckle tracking echocardiography analysis 17
The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease 16
SWITCH TO AGALSIDASE ALFA AFTER THE SHORTAGE OF AGALSIDASE BETA IN FABRY DISEASE: A SYSTEMATIC REVIEW WITH METANALYSIS OF THE LITERATURE 15
Association between Left Atrial Deformation and Brain Involvement in Patients with Anderson-Fabry Disease at Diagnosis 14
Multiple sclerosis and fabry Disease, two sides of the coin? The case of an Italian family 13
Role of serial cardiac 18F-FDG PET-MRI in Anderson-Fabry disease: a pilot study 13
Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease. 12
Left ventricular radial strain impairment precedes hypertrophy in Anderson-Fabry disease 12
Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report. 12
Therapeutic advances in ADPKD: the future awaits 12
Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease Case Reports 10
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial 10
The Retinal Vessel Density as a New Vascular Biomarker in Multisystem Involvement in Fabry Disease: An Optical Coherence Tomography Angiography Study 9
Methylome Profiling in Fabry Disease in Clinical Practice: A Proof of Concept 9
RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study 8
Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature 8
Parapelvic Cysts: An Imaging Marker of Kidney Disease Potentially Leading to the Diagnosis of Treatable Rare Genetic Disorders? A Narrative Review of the Literature 7
Familial polycystic kidneys with no genetic confirmation: Are we sure it is ADPKD? 6
A pilot study of circulating microRNAs as potential biomarkers of Fabry disease 6
Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin 5
Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3-5: Are They Robust? A Fragility Index Analysis 3
The Case | A patient with autosomal dominant polycystic kidney disease with an atypical kidney magnetic resonance image 1
Totale 2.173
Categoria #
all - tutte 6.180
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.180


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201975 0 0 3 2 3 16 14 7 8 6 5 11
2019/2020285 86 10 8 20 5 11 4 17 34 41 32 17
2020/2021300 4 3 11 6 28 18 10 16 34 13 23 134
2021/2022450 4 0 5 4 7 11 28 18 33 52 116 172
2022/2023571 75 44 26 41 55 69 9 57 97 53 30 15
2023/2024156 23 92 41 0 0 0 0 0 0 0 0 0
Totale 2.173